The Global Parkinson’s disease market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD). Recently, there have been some major product launches in Parkinson’s disease. For instance, in February 2022, Avion Pharmaceuticals LLC announced the commercial launch of DHIVY, the first and only carbidopa/ levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in Nov 2021. This unique design enables more precise medication for those with Parkinson’s disease (PD). Also, government funding for research and massive utilization of L-Dopa, asymptomatic dopamine replacement treatment, and the nigrostriatal system expects a boost to the market in the coming years.
To Request a Sample of our Report on Parkinson’s Disease Drug Market: https://www.omrglobal.com/request-sample/parkinsons-disease-drug
The shifting of research activities from symptomatic treatment to Parkinson’s disorder modifying treatment will create growth for Parkinson’s disease treatment industry over the forthcoming years. For instance, Kyowa Kirin Co Ltd a Japanese Pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). For instance, in Feb 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age or older. It can be taken with or without food.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
By Mechanism of Action
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Land- AbbVie Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Bausch Health Companies Inc., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., and others.
A full Report of Parkinson’s Disease Drug Market is Available @ https://www.omrglobal.com/industry-reports/parkinsons-disease-drug
Parkinson’s Disease Drug Market Segmentation
By Mechanism of Action
- Dopamine Agonists
- Anticholinergic
- MAO-B Inhibitors
- Amantadine
- Carbidopa- levodopa
- COMT Inhibitors
- Others
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Company Profiles
- AbbVie Inc
- Apotex Inc
- Axovant Gene Therapies Ltd
- Boston Scientific Corp
- Cipla Inc
- Eisai Co Ltd
- Eli Lily & Co
- Impax Laboratories Inc
- Mylan NV
- Novartis International AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceuticals Industries Ltd
- Wockhardt Ltd
- Orion Corp
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/parkinsons-disease-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
